Current Oncology (Apr 2024)

Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update

  • Shinji Tsukamoto,
  • Andreas F. Mavrogenis,
  • Tomoya Masunaga,
  • Kanya Honoki,
  • Hiromasa Fujii,
  • Akira Kido,
  • Yasuhito Tanaka,
  • Costantino Errani

DOI
https://doi.org/10.3390/curroncol31040157
Journal volume & issue
Vol. 31, no. 4
pp. 2112 – 2132

Abstract

Read online

Curettage is recommended for the treatment of Campanacci stages 1–2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1–3 doses of preoperative denosumab treatment. Denosumab monotherapy once every 3 months is currently the standard strategy for inoperable patients and those with metastatic GCTB. However, in case of tumor growth, a possible malignant transformation should be considered. Zoledronic acid appears to be as effective as denosumab; nevertheless, it is a more cost-effective option. Therefore, zoledronic acid may be an alternative treatment option, particularly in developing countries. Surgery is the mainstay treatment for malignant GCTB.

Keywords